Novel liposomal formulation for targeted gene delivery
- PMID: 17385024
- DOI: 10.1007/s11095-006-9224-x
Novel liposomal formulation for targeted gene delivery
Abstract
Purpose: Development of a polyethylene glycol (PEG)-stabilized immunoliposome (PSIL) formulation with high DNA content suitable for in vivo intravenous administration and targeted gene delivery.
Materials and methods: Plasmid DNA was condensed using 40% ethanol and packaged into neutral PSILs targeted to the mouse transferrin receptor using monoclonal antibodies (MAbs; clones RI7 and 8D3) attached to their PEG maleimide moieties. PSILs size was measured by quasi-elastic light scattering. The targeting capacity of the formulation was determined by transfection of mouse neuroblastoma Neuro 2A (N2A) cells with PSIL-DNA complexes conjugated with either RI7 or 8D3 MAbs.
Results: DNA encapsulation and MAb conjugation efficiencies averaged 71 +/- 14% and 69 +/- 5% (mean +/- SD), respectively. No alteration in mean particle size (< 100 nm) or DNA leakage were found after 48 h storage in a physiological buffer, and the in vivo terminal half-life reached 23.9 h, indicating that the PSIL-DNA formulation was stable. Addition of free RI7 MAbs prevented transfection of N2A cells with PSIL-DNA complexes conjugated with either RI7 or 8D3 MAbs, confirming that the transfection was transferrin receptor-dependent.
Conclusions: The present data suggest that our new PSIL formulation combines molecular features required for targeted gene therapy including high DNA encapsulation efficiencies and vector-specific transient transfection capacity.
Similar articles
-
Brain uptake of a fluorescent vector targeting the transferrin receptor: a novel application of in situ brain perfusion.Mol Pharm. 2014 Jan 6;11(1):243-53. doi: 10.1021/mp400421a. Epub 2013 Nov 22. Mol Pharm. 2014. PMID: 24215184
-
Subcutaneous liposomal delivery improves monoclonal antibody pharmacokinetics in vivo.Acta Biomater. 2025 Mar 15;195:522-535. doi: 10.1016/j.actbio.2025.02.035. Epub 2025 Feb 16. Acta Biomater. 2025. PMID: 39965705
-
Targeting rat anti-mouse transferrin receptor monoclonal antibodies through blood-brain barrier in mouse.J Pharmacol Exp Ther. 2000 Mar;292(3):1048-52. J Pharmacol Exp Ther. 2000. PMID: 10688622
-
A sterically stabilized immunolipoplex for systemic administration of a therapeutic gene.Gene Ther. 2004 Oct;11(19):1434-40. doi: 10.1038/sj.gt.3302304. Gene Ther. 2004. PMID: 15229629
-
In vivo labeling of brain capillary endothelial cells after intravenous injection of monoclonal antibodies targeting the transferrin receptor.Mol Pharmacol. 2011 Jul;80(1):32-9. doi: 10.1124/mol.111.071027. Epub 2011 Mar 31. Mol Pharmacol. 2011. PMID: 21454448
Cited by
-
Small solutions for big problems: the application of nanoparticles to brain tumor diagnosis and therapy.Clin Pharmacol Ther. 2009 May;85(5):531-4. doi: 10.1038/clpt.2008.296. Epub 2009 Feb 25. Clin Pharmacol Ther. 2009. PMID: 19242401 Free PMC article.
-
Nanotherapeutic treatment of the invasive glioblastoma tumor microenvironment.Adv Drug Deliv Rev. 2022 Sep;188:114415. doi: 10.1016/j.addr.2022.114415. Epub 2022 Jul 3. Adv Drug Deliv Rev. 2022. PMID: 35787387 Free PMC article. Review.
-
Plasmid DNA gene therapy of the Niemann-Pick C1 mouse with transferrin receptor-targeted Trojan horse liposomes.Sci Rep. 2020 Aug 7;10(1):13334. doi: 10.1038/s41598-020-70290-w. Sci Rep. 2020. PMID: 32770132 Free PMC article.
-
Novel RGD-lipid conjugate-modified liposomes for enhancing siRNA delivery in human retinal pigment epithelial cells.Int J Nanomedicine. 2011;6:2567-80. doi: 10.2147/IJN.S24447. Epub 2011 Oct 26. Int J Nanomedicine. 2011. PMID: 22128247 Free PMC article.
-
Muscone/RI7217 co-modified upward messenger DTX liposomes enhanced permeability of blood-brain barrier and targeting glioma.Theranostics. 2020 Mar 4;10(10):4308-4322. doi: 10.7150/thno.41322. eCollection 2020. Theranostics. 2020. PMID: 32292496 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources